Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Other Accumulated Expenses (2019 - 2025)

Fulcrum Therapeutics (FULC) has disclosed Other Accumulated Expenses for 7 consecutive years, with $258000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 44.28% to $258000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $258000.0, a 44.28% decrease, with the full-year FY2025 number at $258000.0, down 44.28% from a year prior.
  • Other Accumulated Expenses was $258000.0 for Q4 2025 at Fulcrum Therapeutics, down from $463000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $463000.0 in Q4 2024 to a low of $42000.0 in Q2 2021.
  • A 5-year average of $269888.9 and a median of $306000.0 in 2024 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 46.15% in 2021, then surged 277.14% in 2023.
  • Fulcrum Therapeutics' Other Accumulated Expenses stood at $74000.0 in 2021, then skyrocketed by 41.89% to $105000.0 in 2022, then soared by 277.14% to $396000.0 in 2023, then increased by 16.92% to $463000.0 in 2024, then crashed by 44.28% to $258000.0 in 2025.
  • Per Business Quant, the three most recent readings for FULC's Other Accumulated Expenses are $258000.0 (Q4 2025), $463000.0 (Q4 2024), and $400000.0 (Q3 2024).